Friday, 24 Jan 2020

You are here

EULAR Updates Gout Guidelines

A EULAR task force of 24 individuals (including 15 rheumatologists) have updated their previous 2006 guidelines for gout.  The current update is based on a systematic literature review and a Delphi consensus approach to recommendations.

Among the 11 key recommendations there were recommendations for :

  • Education
  • Non-pharmacological management
  • Frequent flares and contraindications to colchicine: NSAIDs and corticosteroids, or an interleukin-1 blocker could be considered.
  • Treatment of flare: colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), oral or intra-articular steroids or a combination are recommended.
  • Urate-lowering therapy (ULT) should be considered from the first presentation of the disease,
  • Prophylaxis against flares should be given during the first 6 months of ULT, with colchicine, 0.5–1 mg/day or with low dose NSAIDs.
  • Serum uric acid (SUA) levels should be maintained at <6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe (or tophaceous) gout.
  • Allopurinol is recommended as first-line ULT (dosage adjusted according to renal function).
  • With normal kidney function, the starting dose of allopurinol should be 100 mg/day, increasing by 100 mg increments every 2–4 weeks if required, to reach the uric acid target.
  • Febuxostat should be used if the SUA target cannot be achieved with allopurinol or if allopurinol is not tolerated.
  • Pegloticase is recommended for patients with refractory gout. 

The authors recognize that new data and new drugs will call for new guidelines and newer therapeutic strategies to improve the quality of gout care.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.